Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 in Moderately to Severely Active Ulcerative Colitis
NCT07650942Phase 3Not yet recruiting
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Jun 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 3 trial of mufemilast in ulcerative colitis (UC), sponsored by Hemay Pharmaceutical Technology. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
mufemilast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07650942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650942.